Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease
Raphael Loisl(Johannes Kepler University of Linz), Johannes Clausen(Johannes Kepler University of Linz), Sigrid Machherndl‐Spandl(Krankenhaus der Elisabethinen), Christoph Aichinger(Krankenhaus der Elisabethinen), Emine Kaynak(Krankenhaus der Elisabethinen), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Robert Milanov(Krankenhaus der Elisabethinen), Michaela Binder(Durham University), Alexander Nikoloudis(Johannes Kepler University of Linz), Dagmar Wipplinger(Krankenhaus der Elisabethinen), Petra Hasengruber(Krankenhaus der Elisabethinen), Anna Bauhofer(Krankenhaus der Elisabethinen), Hildegard Greinix(Medical University of Graz), Daniel Wolff(University Hospital Regensburg), Olga Saini(Johannes Kepler University of Linz), Irene Straßl(Krankenhaus der Elisabethinen), Andreas Petzer
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273